All articles A–Z
519,064 articles
Carchemish
Carchemish (Karkamish, Assyrian Gargamis) was an ancient city on the Euphrates at today's Turkey-Syria border, capital of the most powerful Neo-Hittite kingdom until its annexation by Assyria in 717 BC.
Carchemish inscriptions
The Carchemish inscriptions, also called the Carchemish hieroglyphic Luwian corpus, are Iron Age Hieroglyphic Luwian texts from Karkemish, the largest corpus from any single Neo-Hittite site.
Carcinisation
Carcinisation, also spelled carcinization, is convergent evolution in which crustaceans independently evolve a crab-like body plan, named in 1916 and seen at least five times.
Carcinoembryonic antigen
Carcinoembryonic antigen (CEA), a glycoprotein tumor marker discovered by Gold and Freedman in 1965 at McGill, is used mainly to monitor colorectal cancer treatment and recurrence, not for screening.
Carcinogen
Carcinogen: any agent (chemical, radiation, virus, or exposure) that can cause cancer. Classified by IARC Groups 1–3 (135 Group 1 agents), NTP, and EPA; hazard classification differs from risk level.
Carcinogenesis
Carcinogenesis: the multistage process by which normal cells become malignant through accumulated genetic and epigenetic changes. Covers initiation-promotion-progression, driver mutation counts, mutational signatures, DNA repair defects, and carcinogens.
Carcinogenicity of polycyclic arylamines
The carcinogenicity of polycyclic arylamines is their tendency to cause human bladder cancer, best proven for 4-aminobiphenyl, an IARC Group 1 carcinogen formerly used in dyes and rubber.
Carcinoid
Carcinoid, coined by Oberndorfer in 1907, is the older name for a well-differentiated neuroendocrine tumor of the GI tract or lung; WHO 2000 replaced it with NET/NEC; carcinoid syndrome occurs with liver metastases.
Carcinoid syndrome
Carcinoid syndrome is a group of symptoms caused when gastrointestinal carcinoid tumors release serotonin and other substances, typically after the tumor has spread to the liver.
Carcinoma
Carcinoma: cancer arising from epithelial cells lining skin and internal organs; the most common cancer type (80-90% of cases). Subtypes include adenocarcinoma, squamous, basal cell, and transitional cell carcinoma; distinct from sarcoma, leukemia, lymphoma, myeloma.
Carcinoma in situ
Carcinoma in situ, also known as in situ neoplasm, is a stage 0 condition in which cells that look like cancer remain confined to the tissue where they formed.
Carcinoma in situ of bladder
Bladder carcinoma in situ (CIS, stage 0is/Tis): flat, always high-grade, noninvasive urothelial cancer of the bladder lining; primary, concomitant, or secondary; ~54% progress untreated; treated with BCG or cystectomy.
Carcinoma in situ of breast
Carcinoma in situ of the breast (DCIS, LCIS; stage 0 breast cancer, intraductal carcinoma): noninvasive lesions confined to breast ducts or lobules; 15–25% of diagnoses, over 98% five-year survival, central overdiagnosis and active surveillance debate.
Carcinoma in situ of colon
Carcinoma in situ of the colon, also called intramucosal carcinoma or stage 0 (Tis N0 M0) colorectal cancer, is abnormal cancer-appearing cells confined to the colonic mucosa, with no metastatic risk and definitive treatment by endoscopic resection.
Carcinoma in situ of endometrium
Carcinoma in situ of endometrium (ICD-11 2E67.0, ICD-10-CM D07.0): abnormal cancer-like cells confined to the uterine lining without invasion; covers the legacy term for endometrial precancer (AH/EIN) and serous endometrial intraepithelial carcinoma.
Carcinoma in situ of larynx
Carcinoma in situ of the larynx (ICD-10 D02.0, stage 0 laryngeal cancer) is non-invasive malignant-appearing epithelium of the voice box, grouped with severe dysplasia, treated by laser endoscopic excision or radiotherapy with surveillance.
Carcinoma in situ of penis
Carcinoma in situ of the penis, also called penile intraepithelial neoplasia grade III, erythroplasia of Queyrat (glans), or Bowen's disease (shaft), is a noninvasive full-thickness squamous atypia, HPV-related, with up to 30% untreated progression risk.
Carcinoma in situ of rectum
Carcinoma in situ of the rectum is stage 0 rectal cancer in which abnormal cells remain in the rectum's innermost lining, with almost no risk of spread.
Carcinoma in situ of skin
Carcinoma in situ of skin, also called Bowen disease or intraepidermal squamous cell carcinoma (ICD-11 2E64), is full-thickness epidermal dysplasia without dermal invasion, mainly UV-, HPV-, and immunosuppression-driven, with 3–5% progression risk to invasive SCC and surgical excision as the most effective treatment.
Carcinoma in situ of stomach
Carcinoma in situ of stomach, also called stage 0 gastric cancer or Tis, is non-invasive high-grade dysplasia of the gastric mucosa (ICD-11 2E60.2), managed by endoscopic resection and discouraged as a term by WHO.
Carcinoma in situ of the conjunctiva
Carcinoma in situ of the conjunctiva (conjunctival squamous cell carcinoma in situ, CIN III/CIS, ICD-11 2E6A.0) is a preinvasive, full-thickness conjunctival epithelial dysplasia with intact basement membrane, treated by excision with cryotherapy or topical chemotherapy.
Carcinoma in situ of the cornea
Carcinoma in situ of the cornea (ICD-11 2E6A.1) is a preinvasive ocular surface squamous neoplasia stage: full-thickness corneal epithelial atypia with intact basement membrane, caused mainly by UV-B, treated by excision or topical chemotherapy.
Carcinoma in situ of trachea
Carcinoma in situ of trachea (ICD-10-CM D02.1) is preinvasive squamous cancer confined to the tracheal lining, detected mainly by advanced bronchoscopy, treatable bronchoscopically, and sometimes regressing.
Carcinoma in situ of vagina
Carcinoma in situ of vagina, also called VaIN 3 or vaginal HSIL, is a full-thickness noninvasive HPV-associated precancerous vaginal lesion, rare (0.2–2 per 100,000 women yearly), treated by laser, excision, brachytherapy, or topical agents.
Carcinoma of the ampulla of Vater
Carcinoma of the ampulla of Vater (ampullary cancer, ampullary carcinoma): rare cancer at the bile-pancreatic duct junction in the duodenum; presents with painless jaundice; treated mainly by Whipple procedure; intestinal subtype fares better than pancreatobiliary.
Carcinomas of ovary
Carcinomas of ovary (ICD-11 2C73.0), malignant epithelial ovarian tumors grouped with fallopian tube and primary peritoneal cancer; five WHO histotypes, high-grade serous most common, treated with surgery and platinum-taxane chemotherapy.
Carcinosarcoma of the cervix uteri
Carcinosarcoma of the cervix uteri, or cervical carcinosarcoma, is a rare, aggressive cervical cancer with both carcinomatous and sarcomatous components, accounting for less than 1% of cervical cancers.
Carcinosarcoma of the corpus uteri
Uterine carcinosarcoma, formerly malignant mixed Müllerian tumor (MMMT), is a rare aggressive biphasic uterine cancer with malignant epithelial and sarcoma components, TP53-mutated, treated by surgical staging plus carboplatin-paclitaxel chemotherapy, with poor survival.
Carcinoscorpius rotundicauda
Carcinoscorpius rotundicauda, the mangrove horseshoe crab (Southeast Asian horseshoe crab), the sole species of its genus and one of four living Limulidae; mangrove- and estuary-bound Asian horseshoe crab with IUCN Data Deficient status, a 1.7 Gb genome, and cryptic population structure.
Carcinus maenas
Carcinus maenas, the European green crab or shore crab, is a portunid crab native to Atlantic Europe and North Africa, now among the IUCN's 100 worst invasive species, preying on bivalves and competing with native crabs on every temperate continent.